Interpreting the reasons for the choice and changing of two drug regimens in an observational cohort: comparison of a ritonavir‐boosted protease inhibitor‐based versus a nonnucleoside reverse transcriptase inhibitor‐based first‐line regimen
Inmaculada Jarrín(Instituto de Salud Carlos III), Santiago Moreno(Universidad El Bosque), Beatriz Hernández‐Novoa(Hospital Universitario Ramón y Cajal), Belén Alejos, Ignacio de los Santos, José Ramón Blanco, Antonio Antela(Universidade de Santiago de Compostela), José López‐Aldeguer(Hospital de Basurto), Félix Gutiérrez(Universitat de Miguel Hernández d'Elx), Melchor Riera(Instituto de Salud Carlos III), Rafael Rubio(Research Institute Hospital 12 de Octubre)
Cited by 7
Related Papers
Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19
|JAMA|2021|728